Mabwell’s Maiweijian (Biosimilar, Denosumab; 120mg) Receives the NMPA approval for Marketing Authorization in China
Shots:
- The NMPA approved Mabwell’s Maiweijian (Biosimilar, Denosumab; 120mg), an anti-RANKL mAb, to treat unresectable giant cell tumors of the bone or resectable’s which may lead to severe functional impairment
- Maiweijian vs XGEVA (original product) has shown similarity in PK, PD, clinical efficacy and safety in patients with solid tumor bone metastases
- The P-I & P-III clinical studies results of the denosumab biosimilar were published in the "International Immunopharmacology" in 2022 and the international journal "JAMA Oncology" in 2024, respectively. Additionally, Mabwell is advancing marketing efforts of MAIWEIJIAN for other indications
Ref: Mabwell | Image: Mabwell
Related News:- Mabwell Highlights Results from the P-III Study of MW032 (Biosimilar, Denosumab) for Solid Tumors in JAMA Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
